KLP Kapitalforvaltning AS Invests $2.16 Million in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

KLP Kapitalforvaltning AS acquired a new stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 17,800 shares of the biotechnology company’s stock, valued at approximately $2,164,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Wellington Management Group LLP boosted its stake in Sarepta Therapeutics by 32.3% during the 3rd quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock valued at $340,527,000 after purchasing an additional 665,087 shares during the period. Erste Asset Management GmbH acquired a new position in shares of Sarepta Therapeutics during the third quarter worth approximately $79,425,000. Janus Henderson Group PLC boosted its position in shares of Sarepta Therapeutics by 14.2% in the third quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock valued at $544,408,000 after acquiring an additional 543,143 shares during the period. Soros Fund Management LLC acquired a new stake in shares of Sarepta Therapeutics in the third quarter worth $25,800,000. Finally, Swedbank AB bought a new position in Sarepta Therapeutics during the fourth quarter worth $16,706,000. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Sarepta Therapeutics

In other news, Director Claude Nicaise sold 2,491 shares of the firm’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the sale, the director now directly owns 27,812 shares in the company, valued at approximately $2,771,187.68. This trade represents a 8.22 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Stock Down 1.5 %

Shares of SRPT opened at $71.81 on Friday. The company has a market capitalization of $6.97 billion, a P/E ratio of 57.45 and a beta of 0.79. Sarepta Therapeutics, Inc. has a one year low of $70.91 and a one year high of $173.25. The business’s 50 day simple moving average is $103.61 and its 200-day simple moving average is $116.46. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03.

Wall Street Analysts Forecast Growth

SRPT has been the subject of a number of research reports. HC Wainwright reissued a “sell” rating and issued a $75.00 price target on shares of Sarepta Therapeutics in a report on Wednesday, March 19th. Deutsche Bank Aktiengesellschaft reduced their target price on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating for the company in a research note on Wednesday, March 19th. Scotiabank lowered their price target on Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating on the stock in a research note on Thursday, March 20th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $163.00 price objective on shares of Sarepta Therapeutics in a research report on Tuesday, March 18th. Finally, Royal Bank of Canada lowered their price objective on Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating on the stock in a research report on Thursday, February 27th. One analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $167.41.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.